IBD生物制剂与病原体特异性血流感染:丹麦全国病例对照研究
该研究基于丹麦全国登记数据,纳入2010-2024年4503例IBD血流感染病例和22473例对照,评估TNFi、维得利珠单抗和乌司奴单抗当前使用与血流感染的关系。结果显示TNFi使用与血流感染率升高相关(aIRR 1.73),而维得利珠单抗和乌司奴单抗未显示升高。病原体分析提示TNFi与大肠埃希菌和金黄色葡萄球菌血流感染相关,维得利珠单抗与粪肠球菌血流感染相关。
要点
- TNFi使用与IBD患者血流感染率升高相关(aIRR 1.73)。
- 维得利珠单抗和乌司奴单抗未显示血流感染率升高。
- TNFi与大肠埃希菌和金黄色葡萄球菌血流感染相关。
核心结论
- TNFi使用与IBD患者血流感染率升高相关,而维得利珠单抗和乌司奴单抗使用未显示升高。
- 不同生物制剂可能存在感染风险差异及病原体特异性易感性差异。
研究设计与样本
- 全国性登记基于的病例对照研究,纳入2010-2024年首次微生物学确诊血流感染且诊断为IBD的个体为病例。
- 每个病例按风险集抽样匹配5名IBD对照,当前生物制剂使用定义为索引日期前180天内记录使用TNFi、维得利珠单抗或乌司奴单抗。
- 采用条件logistic回归估计调整发病率比(aIRR)及95%置信区间(CI)。
主要发现
- 共纳入4503例病例和22473例对照。
- TNFi使用与较高的血流感染率相关(aIRR 1.73,95% CI 1.49-2.00),而维得利珠单抗(aIRR 0.85,95% CI 0.61-1.20)和乌司奴单抗(aIRR 0.68,95% CI 0.38-1.23)使用未显示相关。
- 病原体特异性分析中,TNFi使用与大肠埃希菌和金黄色葡萄球菌血流感染率升高相关,维得利珠单抗使用与粪肠球菌血流感染率升高相关。
- 联合糖皮质激素使用与TNFi和维得利珠单抗使用者相比单药治疗的血流感染率升高相关。
临床怎么用
- 在IBD患者中选用TNFi时应评估血流感染风险,尤其是特定病原体感染风险。
- 维得利珠单抗和乌司奴单抗未显示血流感染率升高,但需注意维得利珠单抗与粪肠球菌血流感染的关联。
- 联合糖皮质激素可能增加血流感染风险,应谨慎评估联合用药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologic drugs have substantially expanded treatment options for inflammatory bowel disease (IBD), but infection risk during exposure remains a concern. AIMS: To investigate the association between current use of tumour necrosis factor-α inhibitors (TNFi), vedolizumab and ustekinumab and bloodstream infection (BSI) in individuals with IBD. METHODS: Nationwide, registry-based case-control study including all individuals with a first-time microbiologically confirmed BSI from 2010 to 2024 and an IBD diagnosis (cases). Each case was matched with five controls with IBD using risk-set sampling. Current biologic use was defined as recorded use of either TNFi, vedolizumab or ustekinumab within 180 days before the index date. Adjusted incidence rate ratios (aIRR) with 95% confidence intervals (CIs) were estimated using conditional logistic regression. RESULTS: We included 4503 cases and 22,473 controls. TNFi use was associated with higher BSI rates compared with no current biologic use (aIRR 1.73, 95% CI 1.49-2.00), whereas vedolizumab (aIRR 0.85, 95% CI 0.61-1.20) and ustekinumab (aIRR 0.68, 95% CI 0.38-1.23) use was not. In pathogen-specific analyses, TNFi use was associated with higher rates of BSI caused by Escherichia coli and Staphylococcus aureus, while vedolizumab use was associated with higher rates of Enterococcus faecium BSI. Concomitant glucocorticoid use was associated with increased BSI rates among TNFi and vedolizumab users compared with monotherapy. CONCLUSIONS: TNFi use was associated with increased BSI rates in patients with IBD, whereas vedolizumab and ustekinumab use was not. Overall, the findings suggest potential differences in infection risk across biologic therapies and in pathogen-specific susceptibility.
引用
- Leding C, Meddis A, Holler JG, et al. Pathogen-Specific Bloodstream Infections Associated With Tumour Necrosis Factor-α Inhibitors, Vedolizumab and Ustekinumab in Inflammatory Bowel Disease: A Danish Nationwide Case-Control Study 2010-2024. Aliment Pharmacol Ther. 2026. PMID: 42782057. doi:10.1111/apt.70999
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。